192 related articles for article (PubMed ID: 29142174)
1. Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis.
Higa A; Hoshi H; Yanagisawa Y; Ito E; Morisawa G; Imai JI; Watanabe S; Takagi M
J Toxicol Sci; 2017; 42(6):755-761. PubMed ID: 29142174
[TBL] [Abstract][Full Text] [Related]
2. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
3. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
[TBL] [Abstract][Full Text] [Related]
4. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
[TBL] [Abstract][Full Text] [Related]
5. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
Lu HR; Hortigon-Vinagre MP; Zamora V; Kopljar I; De Bondt A; Gallacher DJ; Smith G
J Pharmacol Toxicol Methods; 2017 Sep; 87():53-67. PubMed ID: 28501647
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
[TBL] [Abstract][Full Text] [Related]
7. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
[TBL] [Abstract][Full Text] [Related]
8. Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes.
Pfeiffer ER; Vega R; McDonough PM; Price JH; Whittaker R
J Pharmacol Toxicol Methods; 2016; 81():263-73. PubMed ID: 27095424
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment.
Schocken D; Stohlman J; Vicente J; Chan D; Patel D; Matta MK; Patel V; Brock M; Millard D; Ross J; Strauss DG; Blinova K
J Pharmacol Toxicol Methods; 2018; 90():39-47. PubMed ID: 29155283
[TBL] [Abstract][Full Text] [Related]
10. Assessment of extracellular field potential and Ca
Abi-Gerges N; Pointon A; Oldman KL; Brown MR; Pilling MA; Sefton CE; Garside H; Pollard CE
J Pharmacol Toxicol Methods; 2017; 83():1-15. PubMed ID: 27622857
[TBL] [Abstract][Full Text] [Related]
11. CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information.
Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Tanaka K; Takahashi E; Miyamoto K; Morimura K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Shinozawa T; Saito F; Kunimatsu T
Regul Toxicol Pharmacol; 2017 Aug; 88():238-251. PubMed ID: 28634147
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
[TBL] [Abstract][Full Text] [Related]
13. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
[TBL] [Abstract][Full Text] [Related]
14. Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs.
Blinova K; Schocken D; Patel D; Daluwatte C; Vicente J; Wu JC; Strauss DG
Clin Transl Sci; 2019 Nov; 12(6):687-697. PubMed ID: 31328865
[TBL] [Abstract][Full Text] [Related]
15. High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays.
Gilchrist KH; Lewis GF; Gay EA; Sellgren KL; Grego S
Toxicol Appl Pharmacol; 2015 Oct; 288(2):249-57. PubMed ID: 26232523
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
Takasuna K; Kazusa K; Hayakawa T
Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes.
Watanabe H; Honda Y; Deguchi J; Yamada T; Bando K
J Toxicol Sci; 2017; 42(4):519-527. PubMed ID: 28717111
[TBL] [Abstract][Full Text] [Related]
18. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes.
Yamazaki D; Kitaguchi T; Ishimura M; Taniguchi T; Yamanishi A; Saji D; Takahashi E; Oguchi M; Moriyama Y; Maeda S; Miyamoto K; Morimura K; Ohnaka H; Tashibu H; Sekino Y; Miyamoto N; Kanda Y
J Pharmacol Sci; 2018 Apr; 136(4):249-256. PubMed ID: 29555184
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
20. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
